Concert Pharmaceuticals, Inc. (CNCE)

conpharmaConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that focuses on developing and manufacturing novel medicines by applying the company’s proprietary Deuterated Chemical Entity (DCE) Platform to compounds that have well-characterized pharmacological activity. This type of approach may enable less costly and more efficient drug discovery and clinical development compared to conventional small molecule drug research and development.

With the application of Concert’s extensive knowledge of deuterium chemistry, the company is focusing on the discovery and development of novel small molecule drugs. Their approach begins with systematically identifying approved drugs, advanced clinical candidates, or compounds that have the potential for improvement through deuterium substitution.

Unlike traditional drug discovery methods that have high failure rates, the company’s approach allows for better metabolic properties or better pharmacokinetics, thus enhancing clinical safety, efficacy, and tolerability for improved metabolic profile, bioavailability, and half-life. The company prioritizes candidate compounds according to medical needs, competitive and patent landscapes, commercial opportunity, and strategic fit.

Concert Pharmaceuticals, Inc. has executed on this particular approach in order to become a clinical stage biotechnology company. The company is developing a robust product candidate pipeline in various therapeutic areas. The company’s product candidates include CTP-499 for diabetic nephropathy, CTP-354 for spasticity associated with SCI and MS, AVP-786 for neurologic and psychiatric disorders, CTP-730 for inflammatory diseases, JZP-386 for narcolepsy, C-10068 for pain and seizures, and Deuterated Ivacaftor for CF and COPD.

Concert Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNCE. The company has developed the DCE Platform that consists of proprietary knowledge, information, and techniques that they have developed over the past 7 years. The company has a significant experience in pharmaceutical research and development and deuterium chemistry to product candidates that are optimally deuterated.


Yahoo! Finance: CNCE News

Latest Financial News for CNCE

Did You Manage To Avoid Concert Pharmaceuticals's (NASDAQ:CNCE) 20% Share Price Drop?

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...

Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata. Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our clinical trials and support our mission to develop a new treatment for alopecia areata.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

Concert Pharmaceuticals, Inc. (CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. today announced that it will participate at the following upcoming investor conferences: